ATLANPOLE - Biothérapies

Thinking up tomorrow's medicine



FDA grants orphan drug designation to IFB-088 (Sephin1)

InFlectis BioScience announces today that the US Food and Drug Administration (FDA) has granted orphan drug designation to the InFlectis BioScience drug candidate IFB-088, also known as Sephin1, for the treatment of Charcot-Marie-Tooth disease (CMT). The status confers several commercial advantages on InFlectis BioScience, including an exclusive seven-year marketing period for the drug, exemption from FDA application fees, and tax credits for clinical trials. Inflectis BioScience is member of Atlanpole Biotherapies and supported by Atlanpole.

CESTI IHU: Building on the results of research for the benefit of patients

In order to quickly promote innovation and improve the quality of care, the priority objectives of the CESTI IHU are to support researchers in exploiting the results of research and to develop new treatments and diagnostics in partnership with industry. The CESTI IHU is supported in its valuation approach by the state (ANR), Atlanpole Biotherapies cluster, Atlanpole and the valuation departments of its founding members, Nantes University Hospital, Inserm (Inserm transfer) and Nantes University (SATT Ouest Valorisation). The goal is always the same: that the patient can benefit as quickly as possible from therapeutic advances in the work of physicians and researchers.

Kidney transplant: Hemarina and Brest University Hospital announce the launch of OxyOp clinical trial

Logo Hemarina

A multicenter clinical study with the aim of evaluating the use of HEMO2life, an oxygen carrier for the preservation of kidney transplants waiting to be transplanted, will start in the coming weeks in France and will include 60 patients. The ultimate goal is the marketing of HEMO2life and its use in hospitals. Hemarina is a member of Atlanpole Biotherapies and supported by ID2Santé.

TRONICO and GEPEA CNRS UMR create a joint laboratory: "RIMAE"


The joint laboratory project “RIMAE” (Research and Industrialization of Measures Applied to the Environment) has been selected by the ANR (French National Research Agency). The purpose of this laboratory will be to develop and industrialize the biosensor capable of measuring the toxic effects of chemical compounds. This laboratory will be located on the university campus of La Roche sur Yon. Tronico is a member of Atlanpole Biotherapies.

Your news


The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation


Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005). 

Atlanpole UK